Tunitas Therapeutics, Inc., a San Francisco, CA-based biopharmaceutical company, closed a $10m Series A venture capital financing.
The round was co-led by Ally Bridge Group and WuXi Ventures, with participation from RA Capital Advisors. As part of the transaction, David Nikodem, Ph.D., Managing Director, Ally Bridge Group, and Sophie Qiao, Ph.D., Venture Partner, WuXi Ventures, joined Tunitas’ board of directors.
Led by Nolan Sigal, M.D., Ph.D., President and Chief Executive Officer, Tunitas is developing novel targeted protein therapeutics for allergy sufferers.
The company intends to use the funds to advance its lead fusion protein candidate, epsi-gam, through its initial Phase 1 clinical trials and the initiation of Phase 2a studies. It plans to develop epsi-gam as a potential treatment for patients with moderate to severe asthma and for patients with severe, potentially life-threatening food allergies.